EFIV, BLK, CMCSA, DHR: Large Outflows Detected at ETF
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 05 2025
0mins
Source: NASDAQ.COM
ETF Price Range and Trading Dynamics: EFIV's share price has a 52-week low of $46.165 and a high of $58.93, with the last trade at $53.56; the article discusses the significance of comparing this price to the 200-day moving average for technical analysis.
ETF Units and Market Impact: ETFs function by trading units rather than shares, which can be created or destroyed based on investor demand, affecting the underlying holdings; monitoring changes in shares outstanding helps identify notable inflows and outflows that can impact individual components within ETFs.
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DHR is 261.57 USD with a low forecast of 235.00 USD and a high forecast of 310.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
15 Buy
2 Hold
0 Sell
Strong Buy
Current: 242.050
Low
235.00
Averages
261.57
High
310.00
Current: 242.050
Low
235.00
Averages
261.57
High
310.00
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
